Margot J. Burnell

Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.

Mark N. Levine, V. Bramwell, Kathleen I. Pritchard et al. · Journal of Clinical Oncology · 1998 · 622 citations

Randomized Placebo-Controlled Study of Low-Dose Warfarin for the Prevention of Central Venous Catheter–Associated Thrombosis in Patients With Cancer

Stephen Couban, Michael Goodyear, Margot J. Burnell et al. · Journal of Clinical Oncology · 2005 · 328 citations

Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial

Nick Pavlakis, Katrin Marie Sjoquist, Andrew Martin et al. · Journal of Clinical Oncology · 2016 · 238 citations · Full text

Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer

Margot J. Burnell, Mark N. Levine, Judith‐Anne W. Chapman et al. · Journal of Clinical Oncology · 2009 · 152 citations · Full text

Surgical Oncology, Breast Oncology, Cancer Management +18

Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: An NCIC Clinical Trials Group study

C. Cripps, Margot J. Burnell, Jacques Jolivet et al. · Annals of Oncology · 1999 · 97 citations

Oncology, Multi-targeted Antifolate, Medicine +9